NICE International

How Have HTA Agencies Evolved Their Methods Over Time?

29 April 2024

The many changes in Health Technology Assessment (HTA) methods and processes over time, are a challenge to navigate let alone stay abreast of. This report explores the breadth of variation in past and current positioning of HTA agencies in 14 countries, on five key methodological topics: discount rates, modifiers, patient involvement, real-world evidence (RWE), and surrogate endpoints.

The Future of NICE in a Changing HTA Landscape

11 March 2024

To commemorate NICE’s 25th anniversary, this OHE webinar explored the biggest challenges and opportunities for the NICE HTA program over the next 5-10 years.

The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot

12 October 2022

This second blog focuses on the value assessment used within the NICE-NHS England AMR pilot, which is crucial for capturing an antibiotic’s value so the subscription model can reward those with higher value.

The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance

12 October 2022

Recently the UK became the first country in the world to test a so-called ‘fully delinked model’ to pay for antibiotics. OHE is publishing a series of four blogs to answer the key questions raised by the NICE-NHS England AMR model [and discuss what it means for the future of antibiotic development].

International Decision Support Initiative (iDSI): Mapping of priority-setting in health in 17 low and middle countries across Asia, Latin America, and Africa

1 April 2015

This mapping of priority-setting considers factors such as existence of HTA institutions and commitment to UHC (Brazil, Chile, Colombia, Mexico, Uruguay, Ghana, Kenya, Malawi, South Africa,…